179 related articles for article (PubMed ID: 32683297)
1. RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.
Jin X; Xie H; Liu X; Shen Q; Wang Z; Hao H; Gu Y
Int Immunopharmacol; 2020 Oct; 87():106707. PubMed ID: 32683297
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Biomarker ZNF311 and Its Correlation With Tumor Progression and Immune Infiltrates in Glioma.
Ge X; Jiang S; Wang Z; Hu N; Jiang R; Cai Z; Wu B; Zhang Y; Gong P
World Neurosurg; 2021 Jul; 151():e37-e46. PubMed ID: 33746099
[TBL] [Abstract][Full Text] [Related]
3. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
4. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis regarding the correlation between GAS2 family genes and human glioma prognosis.
Zhao C; Zhang N; Cui X; Zhang X; Ren Y; Su C; He J; Zhang W; Sun X; Yang J; Gao X
Cancer Med; 2021 Apr; 10(8):2826-2839. PubMed ID: 33713047
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
7. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
8. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular immune characterization of ERBB2 in glioma.
Mei J; Wang T; Xu R; Chen D; Zhang Y
Int Immunopharmacol; 2021 May; 94():107499. PubMed ID: 33640859
[TBL] [Abstract][Full Text] [Related]
10. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
11. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma.
Ge X; Wang Z; Jiang R; Ren S; Wang W; Wu B; Zhang Y; Liu Q
Int J Biochem Cell Biol; 2021 Oct; 139():106054. PubMed ID: 34390854
[TBL] [Abstract][Full Text] [Related]
12. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
13. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
14. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
15. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
16. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
17. Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma.
He J; Zeng C; Long Y
Comput Math Methods Med; 2021; 2021():2191709. PubMed ID: 34497663
[TBL] [Abstract][Full Text] [Related]
18. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
19. Tumor Purity as an Underlying Key Factor in Glioma.
Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A
Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819
[No Abstract] [Full Text] [Related]
20.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
